FebriDx®

New Rapid Point-of-Care Test  
for Acute Respiratory Infections

Diagnose acute respiratory infection and differentiate bacterial from non-bacterial etiology

febridx-2

Contact Us For Customized Pricing and Expert Support
  • Identify a bacterial infection and initiate appropriate treatment during a patient visit
  • Improve practice workflow by identifying which patients require attention
  • Ensure that bacterial infections are not overlooked
  • Easily implement an outpatient antimicrobial stewardship solution
test-Jun-14-2024-03-43-15-1508-PM

KEY BENEFITS AND FEATURES

99% negative predictive value to rule out bacterial infections1

Results after 10 minutes from a fingerstick
   

Instrument-free

FDA cleared, easy-to-use procedure
   

SIMPLE INSTRUMENT-FREE
TEST PROCEDURE

 

Steps
Steps 2

1. Shapiro NI, Fil bin MR, Hou PC, et al. Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting. JAMA Network Open. 2022;5(70):e2234588-e2234588. doi:70.7007/jamanetworkopen.2022.,4S88

FebriDX is a registered trademark of Lumos Diagnostics Holdings, Ltd. Verséa is a registered trademark of Verséa Health, Inc.

 1.800.397.0670 
 diagnostics@versea.com
  www.verseadiagnostics.com
©2024 Verséa Diagnostics, LLC. All Rights Reserved.